1. Use of plasma‐derived factor X concentrate in neonates and infants with congenital factor X deficiency
- Author
-
Karen L. Zimowski, Glaivy Batsuli, Corinna L. Schultz, Catherine E. McGuinn, Shipra Kaicker, and Yasmina L. Abajas
- Subjects
Adult ,Pediatrics ,medicine.medical_specialty ,Hemorrhage ,030204 cardiovascular system & hematology ,Vial ,Sepsis ,03 medical and health sciences ,chemistry.chemical_compound ,0302 clinical medicine ,Breakthrough bleeding ,medicine ,Humans ,Dosing ,Family history ,Child ,Factor X Deficiency ,Retrospective Studies ,business.industry ,Factor X ,Infant, Newborn ,Infant ,Hematology ,medicine.disease ,chemistry ,Hemostasis ,Female ,Blood Coagulation Tests ,Blood coagulation disorder ,medicine.symptom ,business - Abstract
BACKGROUND Congenital factor X deficiency (FXD) is a rare bleeding disorder that often presents with severe bleeding in the neonatal period. Long-term prophylaxis with infusions of FX-containing products is recommended in patients with FXD and a personal or family history of severe bleeding. A plasma-derived FX concentrate (pdFX) is approved for on-demand and prophylactic therapy in adults and children with FXD. The safety and efficacy of pdFX has been demonstrated in patients
- Published
- 2020